NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: AstraZeneca
Conditions: HER2-negative
Countries: Argentina, Brazil, Dominican Republic, Hong Kong, India, Indonesia, Malaysia, Mexico
This noninterventional, multicenter,retrospective study has been proposed to estimate the prevalence, clinicopathological characteristics,treatment patterns and clinical outcomes of human epidermal growth factor receptor 2 -(HER2)low locally-advanced or metastatic breast cancer(mBC) by accurate rescoring of archived IHC-stained formalin-fixed paraffin-embedded (FFPE) slides for HER2 in patients previously identified as HER2-negative from emerging markets of international regions (non-US and non-European region) with largely unknown prevalence estimates of HER2 low mBCs. Patients with a confirmed diagnosis of HER2-negative, locally-advanced or mBC regardless of Hormone receptor (HR)status between 01 January 2019 and 31 December 2022 who progressed on any systematic anticancer therapy (eg, ET, chemotherapy, CDK4/6 inhibitor, targeted therapies other than anti-HER2, or immunotherapy) in advanced disease with availability of atleast 12 months of follow-up data (from the index date) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis of locally-advanced or mBC will be enrolled in the study. The HR positive patients will be considered eligible for the study if they have received ET as adjuvant therapy in the early BC setting and progressed within 24 months. This scenario will be considered as progression on systematic treatment in the advanced or metastatic setting.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria:1. Men or women, ≥18 years of age 2. Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted) according to local regulations 3. Must have a histological or cytological confirmed previous diagnosis as HER2-negative (IHC zero, 1+, 2+/ISH-) locally-advanced or mBC between 01 January 2019 and 31 December 2022, regardless of HR status 4. Must have progressed on any systemic anticancer therapy (eg, ET, chemotherapy, CDK4/6 inhibitor, targeted therapies other than anti-HER2, or immunotherapy) in the metastatic setting with the availability of at least 12 months of follow-up data (from the index date) in the medical records at the participating site, unless patient died within the first 12 months of diagnosis a) The HR positive patients will be considered eligible for the study if they have received ET as adjuvant therapy in the early BC setting and progressed within 24 months, this scenario will be considered as progression on systematic treatment in the advanced or metastatic setting 5. Must have historical IHC-stained FFPE tissue from locally-advanced or mBC slides for HER2 in an acceptable quality to allow for accurate rescoring of HER2 expression - Exclusion Criteria:1. Have a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin until 3 years prior to diagnosis of locally-advanced or mBC 2. Patients with historical HER2 status of IHC 2+/ISH+ or 3+, or HER2 amplified \-
- Rosario, Argentina
- São Paulo, Brazil
- Santo Domingo, Dominican Republic
- Hong Kong, Hong Kong
- Bengaluru, Karnataka, India
- Kochi, Kerala, India
- Mumbai, Maharashtra, India
- Bhubaneswar, Odisha, India
- Mohali, Punjab, India
- Hyderabad, Telangana, India
- Varanasi, Uttar Pradesh, India
- Delhi, India
- Delhi, India
- Delhi, India
- Jakarta, Indonesia
- Kaula Lumpur, Malaysia
- Subang Jaya, Malaysia
- Subang Jaya, Malaysia
- Mexico City, Mexico
- Panama City, Panama
- Quezon City, Philippines
- Singapore, Singapore
- Singapore, Singapore
- Singapore, Singapore
- Singapore, Singapore
- Bangkok, Thailand
- Bangkok, Thailand
- Bangkok, Thailand
- Hanoi, Vietnam
- Ho Chi Minh City, Vietnam
- + 1 more on CT.gov